Dianthus Therapeutics Q1 2024 Earnings Report

Dianthus Therapeutics EPS Results

• Actual EPS: -$0.54
• Consensus EPS: -$0.43
• Beat/Miss: Missed by -$0.11
• One Year Ago EPS: N/A

Dianthus Therapeutics Revenue Results

• Actual Revenue: $0.87 million
• Expected Revenue: $0.48 million
• Beat/Miss: Beat by +$390.00 thousand
• YoY Revenue Growth: N/A

Dianthus Therapeutics Announcement Details

• Quarter: Q1 2024
• Date: 5/9/2024
• Time: N/A
• Conference Call Date: Thursday, May 9, 2024
• Conference Call Time: 7:00AM ET

Dianthus Therapeutics (NASDAQ:DNTH) is a clinical-stage biotechnology company focused on the discovery and development of novel RNA-targeted therapies for serious ophthalmic conditions. The company’s research leverages antisense oligonucleotide (ASO) technology to address both inherited and degenerative eye diseases with high unmet medical need. Headquartered in San Diego, California, Dianthus was founded in 2021 as a spin-out from Ionis Pharmaceuticals, inheriting a robust pipeline of ocular programs developed using Ionis’s pioneering RNA platform.

The company’s lead program, DN316, is an ASO therapy in development for the treatment of Fuchs endothelial corneal dystrophy, a hereditary disorder that leads to progressive corneal edema and vision loss. In parallel, Dianthus is advancing DN821, an ASO candidate aimed at neovascular (wet) age-related macular degeneration, and is exploring additional pipeline candidates in preclinical stages for conditions such as diabetic retinopathy and cataracts. Each program is designed to modulate gene expression in ocular tissues through targeted intravitreal or intracameral administration.

Dianthus maintains research and development operations in the United States and collaborates with leading academic institutions and clinical sites across North America and Europe to support its clinical trials. The company’s multidisciplinary team combines expertise in oligonucleotide chemistry, ophthalmology, and drug delivery to overcome challenges associated with achieving therapeutic concentrations in the eye while minimizing systemic exposure.

Leadership at Dianthus includes industry veterans with extensive backgrounds in ophthalmic drug development. The executive team is led by a chief executive officer who previously held senior roles at major biopharmaceutical firms, supported by a chief scientific officer renowned for contributions to RNA therapeutics and a chief medical officer with deep experience in clinical ophthalmology. Together, they guide the company’s strategic vision to bring first-in-class RNA therapies to patients suffering from blinding eye diseases.